PMID

Data

Article Title

Organization

Progress in the development of fatty acid synthase inhibitors as anticancer targets.

University of South Alabama

Fatty Acid Synthase (FASN) Inhibitors as Potential Treatment for Cancer, Obesity, and Liver Related Disorders.

Therachem Research Medilab (India)

Repositioning proton pump inhibitors as anticancer drugs by targeting the thioesterase domain of human fatty acid synthase.

Indiana University School of Medicine

Imidazopyridine-Based Fatty Acid Synthase Inhibitors That Show Anti-HCV Activity and in Vivo Target Modulation.

3-V Biosciences

The lipogenesis pathway as a cancer target.

Wayne State University

Fatty Acid synthase inhibitors as possible treatment for cancer: patent highlight.

TBA

Fatty acid synthase inhibitory activity of acylphloroglucinols isolated from Dryopteris crassirhizoma.

Korea Research Institute of Bioscience and Biotechnology

Structure-activity relationships at the 5-position of thiolactomycin: an intact (5R)-isoprene unit is required for activity against the condensing enzymes from Mycobacterium tuberculosis and Escherichia coli.

National Institute of Allergy and Infectious Diseases

Synthesis and evaluation of analogues of S-adenosyl-L-methionine, as inhibitors of the E. coli cyclopropane fatty acid synthase.

Universit£

Discovery of BI 99179, a potent and selective inhibitor of type I fatty acid synthase with central exposure.

Boehringer Ingelheim Pharma

Discovery of novel fatty acid synthase (FAS) inhibitors based on the structure of ketoaceyl synthase (KS) domain.

Sichuan University

Fatty acid synthase inhibitors of phenolic constituents isolated from Garcinia mangostana.

Chinese Academy of Sciences

Novel fatty acid synthase (FAS) inhibitors: design, synthesis, biological evaluation, and molecular docking studies.

Institute of Pharmacology and Toxicology

1-Oxo-3-substitute-isothiochroman-4-carboxylic acid compounds: synthesis and biological activities of FAS inhibition.

Institute of Pharmacology & Toxicology

3-Aryl-4-hydroxyquinolin-2(1H)-one derivatives as type I fatty acid synthase inhibitors.

Merck Research Laboratories

Therapeutic Activity of the Lansoprazole Metabolite 5-Hydroxy Lansoprazole Sulfide in Triple-Negative Breast Cancer by Inhibiting the Enoyl Reductase of Fatty Acid Synthase.

Indiana University School of Medicine

Galloyl esters of trans-stilbenes are inhibitors of FASN with anticancer activity on non-small cell lung cancer cells.

National University of Singapore

Discovery and optimization of novel piperazines as potent inhibitors of fatty acid synthase (FASN).

Forma Therapeutics

Synthesis, biological activities, and docking studies of d-pantolactone derivatives as novel FAS inhibitors.

Third Institute of Oceanography

CT2108A and B: New fatty acid synthase inhibitors as antifungal agents.

Panlabs

Flavanone glycosides from Miconia trailii.

University of Mississippi

Application of a flexible synthesis of (5R)-thiolactomycin to develop new inhibitors of type I fatty acid synthase.

Johns Hopkins University

Design and synthesis of a series of bioavailable fatty acid synthase (FASN) KR domain inhibitors for cancer therapy.

Janssen Research and Development

A strategy for dual inhibition of the proteasome and fatty acid synthase with belactosin C-orlistat hybrids.

Baylor University

(-)-UB006: A new fatty acid synthase inhibitor and cytotoxic agent without anorexic side effects.

Yachaytech University

Dihalogenated sulfanilamides and benzolamides are effective inhibitors of the three ß-class carbonic anhydrases from Mycobacterium tuberculosis.

Universit?? Degli Studi Di Firenze

Quinazoline-urea, new protein kinase inhibitors in treatment of prostate cancer.

Universit?? Lille Nord De France

Trypanocidal bisbenzylisoquinoline alkaloids are inhibitors of trypanothione reductase.

Orstom

Design of mutation-resistant HIV protease inhibitors with the substrate envelope hypothesis.

University of Maryland

The discovery of novel vascular endothelial growth factor receptor tyrosine kinases inhibitors: pharmacophore modeling, virtual screening and docking studies.

Shanghai Jiao Tong University

Alpha-noradrenergic receptor binding in mammalian brain: differential labeling of agonist and antagonist states.

TBA

Discovery of SCH446211 (SCH6): a new ketoamide inhibitor of the HCV NS3 serine protease and HCV subgenomic RNA replication.

Schering-Plough Research Institute

Structural-thermodynamic relationships of interactions in the N-terminal ATP-binding domain of Hsp90.

University College London